RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

StatusCompleted
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Oct 11, 2023, no change to tracked fieldsv5-v7
  2. Enrollment target: 125 to 29v4 Show 5 more changesShow less
    • Primary completion date: Sep 2006
    • Study completion date: Oct 2004 to Sep 2006
    • Study description expanded, about 32 words
    • Study arms: 0 to 1
    • Eligibility criteria expanded, about 3 words
  3. Trial status: Active, Not Recruiting to Completedv3
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
M.D. Anderson Cancer Center
1,232 trials monitored
See 84 trials at risk
Leukemia
2,976 trials monitored
See 181 trials at risk
Non-Hodgkin Lymphoma
2,031 trials monitored
See 116 trials at risk
Acute Myeloid Leukemia (AML)
1,278 trials monitored
See 76 trials at risk
and 4 more diseases
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis. Another goal is to learn how effective the dose that is found is as a treatment.
Trial Details
NCT Number NCT00081874
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Novartis
Conditions
(from sponsor)		 Leukemia, Mantle Cell Lymphoma, Myelofibrosis
Related terms Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, T-Cell, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis, Recurrence
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov